Robert Carlson

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Albiruni R. Abdul Razak, Morten Mau‐Sørensen, Nashat Gabrail et al. · Journal of Clinical Oncology · 2016 · 247 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Mrinal M. Gounder, Alona Zer, William D. Tap et al. · Journal of Clinical Oncology · 2016 · 165 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

John Kuruvilla, Michael R. Savona, Rachid Baz et al. · Blood · 2017 · 157 citations · Full text

Medicine, Oncology, Pharmacology +11

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Ramiro Garzon, Michael R. Savona, Rachid Baz et al. · Blood · 2017 · 153 citations · Full text

Medicine, Oncology, Pharmacology +10

MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps

Shailaja Kasibhatla, Vijay Baichwal, Sui Xiong Cai et al. · Cancer Research · 2007 · 126 citations

Medicine, Medicinal Chemistry, Pharmacology +16